Monoclonal antibody: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
mNo edit summary |
||
| Line 15: | Line 15: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}}[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 06:00, 21 September 2024
A monoclonal antibody is an immune substance "produced by clones of cells such as those isolated after hybridization of activated B-lymphocytes with neoplastic cells. These hybrids are often referred to as hybridomas." [1] Monoclonal antibodies have extensive applications in clinical medicine and immunochemistry.
The World Health Organization is refining naming conventions for monoclonal antibodies. [2] Its original system came from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group.[3]
Naming of monoclonal antibodies is governed by World Health Organization’s International Nonproprietary Name (INN):
- Human monoclonal antibody. INN names end in -umab. Example is olaratumab.
- Humanized monoclonal antibody. INN names end in -zumab. Example is benralizumab.
- Chimeric monoclonal antibody. INN names end in -ximab. Example is rituximab.
References
- ↑ Anonymous (2024), Antibody, monoclonal (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anna-Maija Autere, Nicole Wagner and Georg-Burkhard Kresse from Roche on behalf of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group (2008), "International Nonproprietary Names for monoclonal antibodies: IFPMA proposal", WHO Drug Information 22 (2), pp. 97-107
- ↑ International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group (2008), [http://www.ifpma.org/fileadmin/templates/ifpmaissues/pdfs/2008_03_21_IFPMA_Proposal_for_naming_of_new_monoclonals.pdf Proposal to the WHO INN Expert Group: Principles for naming of new monoclonal antibodies]